Quick answer
Imlunestrant (trade name Zexu, made by Eli Lilly) is an oral selective estrogen receptor degrader (SERD). China's regulator approved it in June 2026 — alone or with the CDK4/6 inhibitor abemaciclib — for adults with ER-positive, HER2-negative, ESR1-mutant locally advanced or metastatic breast cancer after prior endocrine therapy. It became China's first and only approved oral SERD, and the Cancer Hospital of the Chinese Academy of Medical Sciences (CICAMS) began prescribing it, led by Professor Yuan Peng's team [1][2][3].
Key takeaways
- ER-positive, HER2-negative breast cancer is about 70% of cases; endocrine therapy is its backbone, but 20–40% of patients develop ESR1 mutations and resistance [2].
- ESR1 mutations make the estrogen receptor active without estrogen, so drugs that only lower estrogen lose effect; a SERD both blocks and degrades the receptor [2][3].
- Imlunestrant is taken once daily by mouth, unlike injected fulvestrant, improving convenience [1][3].
- In the EMBER-3 trial, imlunestrant alone extended median overall survival by 11.4 months versus standard endocrine therapy; with abemaciclib, median progression-free survival reached 11.1 months with a 51% lower risk of progression or death [1].
- China approved imlunestrant-plus-abemaciclib ahead of other markets — the first oral SERD in China and the first global approval of this combination [3].
The problem: endocrine resistance
Most ER-positive metastatic breast cancers are treated first with an aromatase inhibitor plus a CDK4/6 inhibitor. Over time, many become resistant, and one common driver is an ESR1 mutation that makes the estrogen receptor switch on without estrogen. That is why guidelines now recommend testing for ESR1 mutations when disease progresses on endocrine therapy [1][2].
An oral SERD addresses this directly: it binds the receptor and promotes its degradation rather than merely cutting estrogen supply, and oral dosing avoids the injections of fulvestrant [2][3].
What was reported
At CICAMS, Professor Yuan Peng's team wrote the first prescriptions for eligible patients after approval, and the hospital described the drug as filling a gap for ESR1-mutant endocrine-resistant disease. The 2026 Chinese expert consensus on endocrine therapy and the CSCO breast cancer guidelines both now emphasise ESR1 testing for patients progressing after endocrine treatment [1][2].
This is a regulatory approval and clinical roll-out, not a new trial report. The supporting evidence comes from the EMBER-3 trial [1][4]; real-world benefit and access (including cost and reimbursement) will play out over time [1][3].
The condition in context: ER-positive breast cancer
Breast cancer is the most common cancer among women worldwide, and hormone-receptor-positive disease is the largest subtype.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | Breast cancer is the most common cancer in women, with about 2.3 million new cases a year [5]. | World Health Organization [5] |
| Subtype | About 70% of breast cancers are ER-positive, HER2-negative; endocrine therapy is their backbone [2]. | CICAMS / media [2] |
| Resistance | About 20–40% develop ESR1 mutations during or after endocrine therapy, driving resistance [2]. | CICAMS / media [2] |
Because the ER-positive subtype is so common, a new option for its resistant phase reaches a large population — though it is specifically for ESR1-mutant disease [1][5].
Why it matters
| For the patient | What the report suggests | Source |
|---|---|---|
| New option | A targeted oral drug for ESR1-mutant disease after endocrine failure [1][2]. | [1][2] |
| Convenience | Once-daily oral dosing versus injected fulvestrant [1][3]. | [1][3] |
| Caution | It is for ESR1-mutant disease; testing is required, and access/cost vary [1][2]. | [1][2] |
Availability and limits
- This is an editorial summary of media, hospital and company-information reports, not an independent clinical assessment or a booking channel [1][2][3].
- Imlunestrant is approved in China for ESR1-mutant, ER-positive/HER2-negative advanced breast cancer after prior endocrine therapy — not for all breast cancers [2][3].
- ESR1 mutation testing is required to identify eligible patients [1][2].
- Efficacy figures come from the EMBER-3 trial; individual outcomes vary [1].
- Burden figures describe breast cancer generally and come from WHO, not this drug [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Does my tumour carry an ESR1 mutation? | Only ESR1-mutant disease is eligible; ask for testing at progression [1][2]. |
| Is imlunestrant available and reimbursed here? | Availability and cost differ by hospital and region [3]. |
| Which department handles foreign patients, and in what language? | CICAMS is a working hospital we do not book; confirm international-department coordination and language support. |
| How are testing, prescriptions and follow-up scheduled around travel? | Ongoing oral therapy needs prescription continuity and monitoring; plan accordingly. |
Questions patients ask
What is an oral SERD?
A selective estrogen receptor degrader taken by mouth that both blocks the estrogen receptor and promotes its degradation — useful when ESR1 mutations make the receptor active without estrogen [2][3].
What is imlunestrant approved for in China?
ER-positive, HER2-negative, ESR1-mutant locally advanced or metastatic breast cancer after prior endocrine therapy, alone or with abemaciclib — approved in June 2026 [2][3].
How well does it work?
In the EMBER-3 trial, imlunestrant alone extended median overall survival by 11.4 months versus standard endocrine therapy; with abemaciclib, median progression-free survival was 11.1 months with a 51% lower risk of progression or death [1].
Why does ESR1 testing matter?
The drug targets ESR1-mutant disease specifically; guidelines recommend testing when breast cancer progresses on endocrine therapy [1][2].
Is this relevant to international patients considering breast-cancer care in China?
It is useful context for access to new endocrine drugs in China. CICAMS is a working hospital we do not book — contact its international department directly and confirm candidacy, language support and travel logistics [1][2].